GHRH (1-29) — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

GHRH (1-29)

Also known as: Sermorelin, GH-RH (1-29), hGRF (1-29), hGHRH (1-29), [Nle27]GHRH (1-29)-NH2, GHRH (1-29)-NH2, Growth Hormone-Releasing Hormone (1-29)

Hypothalamic neuropeptide / GH secretagogue — synthetic analog of endogenous growth hormone-releasing hormone

Research chemicalLast updated: October 19, 2026Based on 34 peer-reviewed studies

What it is

GHRH (1-29) is used in clinical testing to assess how well the pituitary gland responds to growth hormone signals, and is studied for treating GH deficiency in children. It works by directly stimulating the pituitary to release its own growth hormone. Not FDA-approved in this form; studied in diagnostic and pediatric applications.

The scientific side

GHRH (1-29) is a 29-amino-acid fragment of endogenous hypothalamic growth hormone-releasing hormone that stimulates GH secretion from the anterior pituitary gland. It acts through the pituitary-type GHRH receptor (pGHRH-R) and its splice variants, particularly SV1, which are expressed on pituitary somatotrophs and — as an autocrine/paracrine system — on a variety of extrapituitary and tumor cells (PMID 18506184, PMID 24186980 [not present — see PMID 12186980]). Receptor binding elevates cAMP and activates downstream signaling cascades including ERK1/2, JAK2/STAT3, MAPK, and PKA pathways (PMID 19897610, PMID 17448980 [not present — see PMID 20232355]). In cancer-focused research, synthetic GHRH antagonists (not the agonist peptide itself) have been developed to block this receptor, suppressing tumor growth and inflammation (PMID 41075421, PMID 32289177). As an agonist, GHRH (1-29) stimulates pulsatile GH release; pulsatile GH release can be reconstituted in vivo by combining continuous GHRH with intermittent somatostatin withdrawal. The GH-releasing effect requires functional somatotrophs: patients with direct pituitary damage show attenuated responses even to supramaximal doses. The D-Ala2 substitution reduces metabolic clearance and extends half-life relative to the native peptide. Note: this is the synthetic 29-residue research fragment; for the full-length endogenous GHRH (1-44), see /peptides/ghrh.

Class: Hypothalamic neuropeptide / GH secretagogue — synthetic analog of endogenous growth hormone-releasing hormone

Administration & storage

Administration
Intravenous bolus (PMID: 10754477PMID: 7921207PMID: 9579235)Intravenous continuous infusion (PMID: 10594518PMID: 8810733PMID: 7962295)Subcutaneous injection — once or twice dailypatient self-administered (PMID: 8772599PMID: 9141536PMID: 9231053PMID: 7955460PMID: 1379256PMID: 9005976PMID: 9360512)Subcutaneous continuous infusion (PMID: 8329829PMID: 10594518)Intranasal insufflation — low bioavailability (~3–5%) reported (PMID: 8329825PMID: 8329828)
Storage
No abstract in the reviewed set explicitly describes storage conditions for GHRH (1-29) preparations.
Cautions
GHRH antibodies developed in nearly all children receiving subcutaneous GHRH(1-29)-NH2 for 6 months, though antibody titers did not correlate with height gain and largely disappeared by 9 months after stopping treatment.,Intranasal GHRH(1-29)-NH2 caused local reactions (sneezing, rhinorrhoea, mild mucosal burning) in most pediatric patients; two children discontinued treatment early; decreasing absorption and antibody development occurred over 6 months.,Mild injection-site irritation was reported in 3 patients receiving subcutaneous GHRH(1-29)-NH2 infusion over 6 months.,Transient hyperlipidemia was observed during 16-week nightly GHRH analog administration in age-advanced adults and resolved by end of study.,Fasting blood glucose and insulin levels increased during 12-month twice-daily GHRH(1-29)NH2 therapy in children with idiopathic short stature; monitoring of glucose metabolism is warranted.,Sterile technique should be used for all injectable preparations to prevent contamination.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification